T1	Participants 386 570	Seven subjects, ages 6-18 years, with autistic disorder completed a 10-week double-blind, crossover trial of clomipramine and desipramine following a 2-week single-blind, placebo phase
T2	Participants 857 949	seven subjects elected to have their children continue to take clomipramine after the study.
